At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

Packaging machines are used to package products or components. This product area includes equipment that forms, fills, seals, wraps, cleans, and packages at different levels of automation. Packaging ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Each of us has enough DNA to reach from here to the sun and back, more than 300 times. How is all of that DNA packaged so tightly into chromosomes and squeezed into a tiny nucleus? Histones are a ...

A version of this story appears in the August 2019 issue of National Geographic magazine. Around tables strewn with Exacto knives, bowls, cutting boards, tape, funnels, and bags of hemp powder ...

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. Diffuse hemispheric glioma is a rare, high-grade ...

One area that often gets overlooked is the psychology of product packaging, especially during a rebrand. Navigating the landscape of product development and marketing can be complex. Amidst the ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

Overall, sustainable packaging solutions encompass a wide array of methods and materials, all aimed at reducing environmental impact and promoting a more environmentally sustainable future.

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...